Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients

摘要: The aim of our study was to assess the predictive value platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte (NLR) in terms survival breast cancer patients. This is an observational 437 patients treated between January 2004 December 2006. Survival status obtained from registry Social Security Death Index. analysis, stratified by NLR PLR quartiles, used evaluate their prognostic values. Patients highest 4th quartiles had higher 5-year mortality rate (30.4 40.3 %) compared those lower three (12.1 8.2 %), p < 0.0001. Multivariate hazard ratios first were 3.68 (1.74–7.77, = 0.001) 3.67 (1.52–8.86, 0.004). Higher only showed a trend with normal lymphocyte count, whereas continued be statistically significant predictor all count subsets. Pretreatment independent long-term patients, pretreatment not superior absolute alone predicting mortality.